Article

Kyprolis Trumps Velcade in Multiple Myeloma Trial

Results released by Amgen, who bought the molecule from Onyx, show that Kyprolis yielded better results when used as second-line in relapsed patients.

Patients with relapsed multiple myeloma benefited more from treatment with Amgen's Kyprolis than with Velcade, an older, rival drug marketed by Takeda, according to results from a study announced by Amgen on Sunday night.

Amgen believes proving Kyprolis' superiority over Velcade in the second-line multiple myeloma treatment setting further justifies the $10.4 billion paid for Onyx Pharmaceuticals, the developer of the drug. Another large study pitting the 2 drugs against each other in newly diagnosed multiple myeloma patients is ongoing with results expected next year.

Link to the Amgen press release:

http://bit.ly/17L8xyQ

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Screenshot of Coral Omene, MD, PhD
ASCO 2025
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Cathy Eng, MD, FACP, FASCO
Nini Wu, MD, Navista
Eileen Peng, PharmD, sitting for a video interview
Related Content
AJMC
June 11th 2025

Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

Brigham Walker, PhD Lalan Wilfong, MD Nicholas Robert, MD Alexander Siebert, PhD J. Russell Hoverman, MD, PhD
A private oncology shared savings plan reduced colon cancer treatment costs. Results varied by tumor, with none in breast cancer and mixed effects in lung cancer.
managed care cast logo
October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
The study identified several molecular markers related to SCLC prognosis by integrating somatic mutation profiles, mRNA transcriptome data, and clinical information. | Image credit: vitstudio - stock.adobe.com
June 6th 2025

Novel Biomarkers May Inform Prognosis in SCLC

AJMC Contributor
The findings provide insight into which patients may have favorable or inferior responses to immunotherapy for small cell lung cancer (SCLC).
Managed Care Cast logo
April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
young adult cancer | Image credit: Roswell Park Cancer Center
June 6th 2025

ASCO Sessions Explore Data and Dynamics of Early-Onset Cancer

Mary Caffrey
Colorectal cancer offered the earliest window into the trend of increased cancer incidence among those younger than age 50. Obesity is among the factors linked to rising rates of cancer in young adults.
FDA headquarters | Image Credit: - Tada Images- stock.adobe.com
June 6th 2025

5 Key FDA Approval Dates Mark a Milestone-Filled May

Brooke McCormick
In May, the FDA granted significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo